文献速递肝病消化道肿瘤与早癌

2021年全球肝癌负担研究

Liver cancer in 2021: Global Burden of Disease study.
PubMed 文献 · J Hepatol · 2024-10-30

该研究基于2021年全球疾病负担研究框架,分析2010至2021年204个国家和地区的成人原发性肝癌发病与死亡趋势及不同病因的贡献。2021年全球肝癌新发病例529,202例、死亡483,875例;2010至2021年新发病例和死亡数分别增加26%和25%,年龄标化发病率和死亡率全球下降但美洲和东南亚上升。HBV仍是全球肝癌发病和死亡的主要病因,MASLD是唯一年龄标化发病率和死亡率均上升的病因。

要点

  • 2021年全球肝癌新发529,202例、死亡483,875例,2010至2021年新发和死亡数分别增加26%和25%。
  • 全球肝癌年龄标化发病率和死亡率下降,但美洲和东南亚上升。
  • HBV仍是全球肝癌发病和死亡的主要病因,MASLD是唯一年龄标化发病率和死亡率均上升的病因。

核心结论

  • 肝癌年龄调整发病率和死亡数已开始下降,但新发病例和死亡的绝对数继续增加,人口增长和老龄化贡献了绝对数与率趋势的分离。
  • 差异持续存在,MASLD相关肝癌的发病率和死亡率继续上升。
  • 病毒性肝炎相关肝癌的年龄调整死亡率下降但仍处高位,而MASLD相关肝癌的年龄调整死亡率上升。
  • 需要持续努力和资源以消除病毒性肝炎、逆转当前大量饮酒趋势并应对MASLD的代谢危险因素。

研究设计与样本

  • 利用2021年全球疾病负担研究的方法学框架,分析2010至2021年204个国家和地区的全球和区域发病与死亡时间趋势及不同病因的贡献。

主要发现

  • 2021年全球估计肝癌新发病例529,202例、死亡483,875例。
  • 2010至2021年全球肝癌新发病例增加26%,死亡增加25%。
  • 全球肝癌年龄标化发病率和年龄标化死亡率下降,但美洲和东南亚上升。
  • HBV仍是全球肝癌新发病例和死亡的主要病因。
  • MASLD是唯一年龄标化发病率和年龄标化死亡率均上升的肝癌病因;酒精相关肝癌的年龄标化发病率和死亡率保持稳定,HBV和HCV相关肝癌的年龄标化发病率和死亡率下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The epidemiology of adult primary liver cancer continues to evolve, owing to the increasing prevalence of metabolic disease, rising alcohol consumption, advances in vaccination for HBV, and antiviral therapy for HCV. Disparities in care and the burden of liver cancer between populations persist. We assess trends in the burden of liver cancer and contributions by various etiologies across 204 countries and territories from 2010 to 2021. METHODS: Utilizing the methodological framework of the Global Burden of Disease Study 2021, we analyzed global and regional temporal trends in incidence and mortality, and the contributions of various etiologies of liver disease. RESULTS: In 2021, there were an estimated 529,202 incident cases and 483,875 deaths related to liver cancer. From 2010 to 2021, global liver cancer incident cases and deaths increased by 26% and 25%, respectively. Age-standardized incidence rates (ASIRs) and death rates (ASDRs) for liver cancer declined globally, but rose in the Americas and Southeast Asia. HBV remained the dominant cause of global incident liver cancer cases and deaths. MASLD (metabolic dysfunction-associated steatotic liver disease) was the only etiology of liver cancer with rising ASIRs and ASDRs. By contrast, ASIRs and ASDRs remained stable for alcohol-related liver cancer, and declined for HBV- and HCV-related liver cancer. CONCLUSIONS: While age-adjusted incidence and deaths from liver cancer have started to decline, the absolute number of incident cases and deaths continues to increase. Population growth and aging contribute to the observed disconnect in the temporal trends of absolute cases and rates. Disparities remain, and the incidence and mortality associated with MASLD-related liver cancer continue to rise. IMPACT AND IMPLICATIONS: Liver cancer remains a major cause of death globally, but its causes and burden in various regions are changing. This study highlights that new diagnoses and deaths related to liver cancer continue to rise. Age-adjusted death rates of liver cancer related to viral hepatitis are declining but remain high. By contrast, age-adjusted death rates of liver cancer related to MASLD (metabolic dysfunction-associated steatotic liver disease) are rising. Sustained efforts and resources are needed to eliminate viral hepatitis, reverse current trends in heavy alcohol use, and tackle the metabolic risk factors of MASLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Tan EY, Danpanichkul P, Yong JN, et al. Liver cancer in 2021: Global Burden of Disease study. J Hepatol. 2024. PMID: 39481652. doi:10.1016/j.jhep.2024.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。